New drugs are needed to treat toxoplasmosis. Toxoplasma gondii calcium-dependent protein kinases (TgCDPKs) are attractive targets because they are absent in mammals. We show that TgCDPK1 is inhibited by low nanomolar levels of bumped kinase inhibitors (BKIs), compounds inactive against mammalian kinases. Cocrystal structures of TgCDPK1 with BKIs confirm that the structural basis for selectivity is due to the unique glycine gatekeeper residue in the ATP-binding site. We show that BKIs interfere with an early step in T. gondii infection of human cells in culture. Furthermore, we show that TgCDPK1 is the in vivo target of BKIs because T. gondii expressing a glycine to methionine gatekeeper mutant enzyme show significantly decreased sensitivity to BKIs. Thus, design of selective TgCDPK1 inhibitors with low host toxicity may be achievable.
a r t i c l e s
The food-borne apicomplexan protozoan Toxoplasma gondii is the causative agent of toxoplasmosis and may be the most common infectious eukaryotic parasite of humans, based on sero-surveys 1 . Most infections are probably transmitted by undercooked meats, but accidental ingestion of cat feces can also transmit toxoplasmosis to humans 2 . T. gondii is an obligate intracellular pathogen that can invade and replicate in most nucleated mammalian cells. Toxoplasmosis remains a major health concern in pregnancy, where it causes severe birth defects or miscarriage, and in immunocompromised hosts, where it causes toxoplasmic encephalitis [3] [4] [5] . Infection is often asymptomatic in immunocompetent hosts, but prolonged disease does occasionally occur 6 . Attack rates in immunocompetent individuals can be high, as evidenced by laboratory-acquired infections 7 , and acute symptoms can be debilitating 8 , warranting T. gondii's classification as a class B agent of concern for biodefense 9 . Toxoplasmosis is extremely difficult to treat, and only limited therapeutics are currently available in the United States (sulfadiazine and pyrimethamine or clindamycin) 10 . These drugs are problematic in that they can cause rash, leucopenia and nephrotoxicity 11 , and sulfadiazine and pyrimethamine can result in complications during pregnancy. New therapeutics against T. gondii are needed.
Calcium levels have long been associated with T. gondii's interrelated processes of invasion, gliding motility and secretion 12 . The intracellular Ca 2+ level oscillates during gliding motility and is promptly dampened upon cell invasion, preventing T. gondii from immediately gliding out of cells 13 . Calcium oscillations control many targets in the cell, and the mediation of invasion, micronemal secretion and gliding motility is thought to be largely due to T. gondii calcium-dependent protein kinases (TgCDPKs) 12, 14 .
Protein kinases are generally attractive targets for new drugs against eukaryotic pathogens 15 , and TgCDPKs are no exception, in part because they are more closely related to CDPKs found in plants and algae than any protein kinases found in mammalian cells 16, 17 . TgCDPK1 is especially attractive for treatment of toxoplasmosis because, in addition to its key role in parasite invasion 14 , it contains a unique sequence variation in the ATP binding pocket: namely, a glycine at the so-called 'gatekeeper position'. This variation distinguishes TgCDPK1from all known mammalian kinases. Thus, design of selective inhibitors may be possible. To this end, we show here that TgCDPK1 is inhibited by low nanomolar levels of bumped kinase inhibitors (BKIs), a class of compounds designed to be inactive against mammalian kinases. Crystal structures of TgCDPK1 in complex with BKIs confirm the structural basis for selectivity and provide a structural look at the Ca 2+ -binding regulatory domain in this class of kinases. Furthermore, we find that BKIs interfere with host-cell invasion in culture, and reverse genetic experiments with live parasites expressing a gatekeeper-residue mutant confirm that TgCDPK1 is indeed the specific target of BKIs in vivo. These studies pave the way for the design of selective drugs against toxoplasmosis.
RESULTS

Enzymology of TgCDPK1
Two types of enzyme assays were developed to follow TgCDPK1 activity: a radiometric scintillation proximity assay measured the labeled a r t i c l e s γ-phosphate of ATP added to a biotinylated peptide substrate, and an ATP consumption assay monitored ATP consumption by luciferase and light production (KinaseGlo). Both assays gave similar results for the K M of the substrates (less than two-fold differences, Supplementary Table 1 and Supplementary Fig. 1a-d Tables 1 and 2 ). As expected, activity of TgCDPK1 on the peptide substrates required addition of exogenous calcium (Supplementary Fig. 2) . Indeed, calcium titration revealed that a concentration of 4.7 µM gave 50% of TgCDPK1 kinase activity.
Structure of TgCDPK1
We have determined X-ray crystal structures of Ca 2+ -free TgCDPK1 in the apo form and in complex with two potent inhibitors ( Fig. 1 and Table 1 ). The structure of the catalytic domain is typical of serine/threonine-type protein kinases. The two Ca 2+ -binding EF hand lobes and the connecting extended helical stem of the calmodulin-like regulatory domain lie along one face of the kinase domain, adjacent to the active site (Fig. 1a) . The kinase and regulatory domains are connected by an intervening helical junction domain characteristic of this class of kinases 18 . The conformation represented by these structures is likely an inactive form of the enzyme, as the calmodulinlike domain occludes the surface required for recognition of target proteins and peptides. Notably, the ATP binding site remains accessible to small-molecule substrates and inhibitors. Comparison of the calcium-free TgCDPK1 structure (Fig. 1a) with the calcium-activated structure 19 (PDB 3HX4) shows that the regulatory domain undergoes major structural rearrangement and is repositioned to lie against the opposite surface of the kinase domain upon calcium binding. This dramatic structural change allows access of the protein substrates to the active site.
Bumped kinase inhibitors bind and inhibit TgCDPK1
Most known kinase inhibitors bind in the ATP binding pocket of the active site 20, 21 . These inhibitors exploit many of the same hydrophobic contacts as the purine ring of ATP and make at least one conserved hydrogen bond to the hinge region. Potent inhibitors also occupy at least one hydrophobic pocket adjacent to the ATP binding site. These additional hydrophobic interactions increase both binding affinity and target selectivity of the inhibitor because sequence heterogeneity is greater among different kinases in these regions. Examination of the TgCDPK1 sequence in the vicinity of the ATP binding pocket (Fig. 1b) shows that it contains a glycine residue at a position that has been termed the gatekeeper residue because it constrains access to the ATP binding site [22] [23] [24] . The glycine at this position in TgCDPK1 (Gly128) is expected to create a much larger pocket off the ATP binding site than is typically observed in protein kinases. Comparison of the TgCDPK1 structure with other kinases shows that this is indeed the case. This difference in the active-site architectures may be exploited for design of selective inhibitors against TgCDPK1.
Previous work 25 has shown that mutation of bulky gatekeeper residues to glycine renders mutant kinases uniquely susceptible to inhibition by BKIs. BKIs are analogs of 4-amino-1-tert-butyl-3-phenylpyrazolo [3,4-d] pyrimidine ( Table 2 ) that are derivatized at the C3 position with bulky aromatic groups 26 . The large side chain of the gatekeeper residue in most kinases prevents bulky aromatic substituents at the C3 position from accessing a hydrophobic pocket at the back of the catalytic cleft, rendering them insensitive to BKI inhibition 22, 23 . Large gatekeeper residues, like methionine or phenylalanine, severely restrict access by the BKIs to a large hydrophobic pocket, whereas small gatekeeper residues, such as the glycine present in TgCDPK1, allow access of BKIs to this hydrophobic pocket 23, 24, 27, 28 . Studies with genetically engineered mice that express mutant kinases with small gatekeeper residues (glycine or alanine), have shown that BKIs preferentially target the mutant kinases [29] [30] [31] . The welldocumented lack of BKI inhibition of mammalian kinases suggests that this class of compounds may be very selective for TgCDPK1 during T. gondii infection [29] [30] [31] .
Based on structural and sequence analysis of the differences in ATP binding sites of typical mammalian kinases and TgCDPK1 with a small gatekeeper (Fig. 1a,b a r t i c l e s (NA-PP1, NA-PP2 and NM-PP1) and showed that two of the three potently inhibit TgCDPK1, with IC 50 values in the nanomolar range ( Table 2) . To show that the glycine gatekeeper is the primary determinant of BKI inhibition, we engineered a glycineto-methionine gatekeeper mutant of TgCDPK1 (G128M). Indeed, the wild-type enzyme was inhibited much more effectively by BKIs compared to the G128M mutant ( Table 2) . For NA-PP1, there was a 175-fold difference between IC 50 values; for NA-PP2, a 1,200-fold difference; and for NM-PP1, a 550-fold difference ( Table 2) . We determined the crystal structures of TgCDPK1 in complex with two potent BKIs (NA-PP2, Fig. 1c and Supplementary Fig. 3a ; NM-PP1, Fig. 1d and Supplementary Fig. 3b ) and, as predicted, these inhibitors bound in the ATP binding site, with the C3 bulky aromatic substituent occupying the pocket adjacent to the glycine gatekeeper. Superposition of an orthologous CDPK containing a methionine gatekeeper onto our BKI complexes showed impairment of the favorable binding mode observed for the BKIs in TgCDPK1 (Fig. 1e) . The bulky gatekeeper side chain clashes with the C3 bulky aromatic substituent, providing a structural basis for the insensitivity of typical kinases toward BKI inhibition, as verified experimentally with the G128M mutant of TgCDPK1 ( Table 2) . These results implicate TgCDPK1 with its unique glycine gatekeeper as a promising drug target for selective treatment of toxoplasmosis.
TgCDPK1 appears in the cytoplasm and nucleus of T. gondii cells
The mode of action of TgCDPK1 is unknown, but its localization in the cell might provide clues to its cellular function. To this end, we fused TgCDPK1 with green fluorescent protein (GFP) to facilitate its localization within live intracellular T. gondii. We found GFPlabeled TgCDPK1 in both the cytosol and the nucleus (Fig. 2a) . We obtained similar findings when the GFP tag was replaced with a C-terminal hemagglutinin (HA) tag (data not shown). Thus, TgCDPK1 may phosphorylate target proteins in both the cytosol and the nucleus.
Effects of BKIs on T. gondii cell entry and growth
We tested three BKIs for effects on host-cell invasion and parasite growth, as earlier work on TgCDPK1 (ref. 14) suggested a key role for this enzyme in T. gondii invasion. BKIs profoundly reduced T. gondii proliferation if added simultaneously with cellular infection (Fig. 2b) and modestly reduced proliferation when added 4 h after the start of invasion (Fig. 2c) . Thus, inhibition of TgCDPK1 activity by BKIs has a stronger effect on invasion than on intracellular growth. This was confirmed by microscopic examination of invasion (data not shown) and is consistent with previous observations on the role of TgCDPK1 (refs. 12,14) . We expect that longer exposure to BKIs would increase the impact of the drug on T. gondii growth as egressed parasites are prevented from invading new cells. We tested each BKI for its effects on human fibroblast replication; the EC 50 values were found to be ~1,000-fold higher (not shown) than those seen in the T. gondii 'invasion' assay.
TgCDPK1 is the dominant in vivo target of BKIs in T. gondii
We transfected the T. gondii cell line with expression plasmids encoding an HA tag fused to the C terminus of either wild-type TgCDPK1 or The IC 50 (µM) values were calculated by nonlinear regression using Prism (GraphPad Software). The assay was performed three times, and the mean IC 50 is shown. The assay was performed using coupling with KinaseGlo at 20 nM TgCDPK1, 10 µM ATP, 40 µM peptide and an incubation time of 30 min.
a r t i c l e s the G128M gatekeeper mutant. Immunoblot analysis showed that the wild-type and G128M mutant TgCDPK1s were expressed to similar levels (Fig. 3a) . Compared to the parental cell line, parasites expressing the G128M mutant were relatively resistant to BKIs NA-PP2 and NM-PP1 when they were added before invasion (Fig. 3b,c) . In contrast, parasites overexpressing the wild-type TgCDPK1 protein showed only a small shift in resistance. Although NA-PP2 was somewhat less effective against wild-type parasites in this experiment, the results were identical in the relative potency of the inhibitors, in that NA-PP2 was more potent than NM-PP1 in blocking T. gondii invasion, following the potency observed against the TgCDPK1 enzyme. Furthermore, in both a microscopic assay of invasion 32 ( Supplementary Fig. 4 ) and a mixed cellular infection using wild-type and G128M mutant TgCDPK1 ( Supplementary  Fig. 5 ), parasites expressing the gatekeeper mutant were markedly resistant to NA-PP2, whereas cells expressing either wild-type TgCDPK1 or GFP controls were not. These findings show that BKIs work primarily through the TgCDPK1 target to prevent T. gondii mammalian-cell entry. (Fig. 1c,d and Supplementary Fig. 3a,b) support the selectivity we observed. Consistent with the proposal that TgCDPK1 is the target of BKIs, the order of increasing potency (NA-PP2 > NM-PP1 > NA-PP1) was identical in both the enzymatic and cellular assays. TgCDPK1 sensitivity to BKIs was altered by deliberate mutation of the gatekeeper glycine residue to a methionine (G128M) that is more typical of mammalian kinases. Expression of this G128M mutant led to resistance in three different types of assays when assessed using model compound NA-PP2 ( Fig. 3b and Supplementary Figs. 4 and 5) . These data support the contention that TgCDPK1 is the major target for BKIs in T. gondii cells. These experimental findings, therefore, address any concerns about quantitative differences between enzyme inhibition and cellular effects, thereby validating the utility of TgCDPK1 structures in complex with BKIs to drive drug development for toxoplasmosis therapy. The concept of using BKIs for the therapy of toxoplasmosis is bolstered by the fact that BKIs have been used in mouse studies with no demonstration of toxicity or troublesome effects to the animals [29] [30] [31] . Therefore, BKIs have promise as a selective drug for toxoplasmosis therapy because they prevent cell entry, and thus the replication, of T. gondii and are likely to be nontoxic to the mammalian host.
DISCUSSION
Because we determined the structure for the inactive, Ca 2+ -free form of TgCDPK1, there may be some concern that this form would not be optimal to guide the design of small-molecule inhibitors with improved potency and selectivity. It is apparent from structural and biochemical studies presented here, however, that small-molecule a r t i c l e s inhibitors can still access the ATP binding site of the Ca 2+ -free conformation of TgCDPK1. Notably, the structure of the active site near the ATP binding pocket, particularly in the vicinity of the gatekeeper residue, the hinge region and the activation loop, is not substantially altered between the structures shown here and that of the Ca 2+ -bound enzyme in complex with adenylyl-imidodiphosphate 19 (PDB 3HX4). Thus, structure-guided optimization of small-molecule inhibitors that target this region is possible using the inactive, Ca 2+ -free form of TgCDPK1. TgCDPK1 was localized in the cytoplasm but also found in the nucleus. Some plant CDPKs are also partially localized to the nucleus. In those CDPKs, nuclear localization is mediated by a signal in the junction domain 18 , but the T. gondii protein is not homologous in this region, and no nuclear localization signal is predicted by standard programs. Because the size of the protein is above the threshold for free diffusion through the nuclear pore, we propose that the protein could bear a noncanonical nuclear-localization sequence or could piggyback into the nucleus on another protein. These results raise the possibility that TgCDPK1 phosphorylates specific nuclear proteins in addition to its presumably cytosolic targets involved in gliding motility. Furthermore, as recently noted, CDPK1 undergoes a large Ca 2+ -dependent structural rearrangement that repositions the regulatory domain to the opposite side of the catalytic domain 19 . This raises the intriguing possibility that Ca 2+ could modulate CDPK1 localization by revealing or occluding the region of the kinase required to mediate nuclear import.
Drug-resistant mutations of the TgCDPK1 gatekeeper to a bulky residue could eventually emerge under selective pressure of BKI therapy. A primary strategy to suppress the emergence of resistance is the coadministration of two drugs targeting different proteins. As TgCDPK1 is not the target of any existing drug, the development of an anti-TgCDPK1 compound could provide a partner drug for coadministration with an existing drug. Most transmission of T. gondii is not from person to person (although this can occur in pregnancy, transplantation or transfusion) but rather through zoonotic cycles where drug pressure is not exerted 1 . This suggests that, if drug resistance emerges, it will largely be confined to the individual, posing little threat to the utility of the drug in other infected persons.
As other apicomplexan pathogens use CDPK enzymes with a small gatekeeper residue, this work may have broader applicability. For instance, the TgCDPK1 ortholog in Cryptosporidium parvum, also an apicomplexan parasite, likewise has a glycine residue at the gatekeeper position (Fig. 1b) , suggesting that BKIs targeting T. gondii could also be effective for the therapy of cryptosporidiosis, another potentially life-threatening infection with poor therapeutics. CDPKs from other apicomplexan parasites have smaller gatekeeper residues, such as serine and threonine (Fig. 1b) . An extended search of all reported human kinase ATP binding pockets found none with a glycine or alanine gatekeeper residue, though ~20% do contain threonine 22 . Thus, the results presented here may have implications in the rational design of anti-apicomplexan CDPK agents devoid of toxic side effects to the host cells.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. Protein Data Bank: Atomic coordinates and structure factors have been deposited with accession numbers 3I79 (apo), 3I7C (NA-PP2 complex) and 3I7B (NM-PP1 complex).
ONLINE METhODS
Expression and purification of mutant and wild-type TgCDPK1. Wild-type TgCDPK1 (GI:12484153, ToxoDB ID 162.m00001) or its G128M mutant was cloned into pAVA0421 containing a cleavable N-terminal hexahistidine tag 33 and expressed in Escherichia coli BL21*(DE3). Expressed protein was purified by nickel-nitrilotriacetic acid affinity and size-exclusion chromatography. The affinity tag was removed by 3C protease cleavage and separated on Ni 2+ Sepharose 6 Fast Flow resin. Fractions were found to be 99% pure by SDS-PAGE.
Site-directed mutagenesis of the gatekeeper residue from glycine to methionine was performed using the QuikChange protocol (Stratagene). Mutation was verified by nucleotide sequence analysis. Detailed description of expression, purification and site-directed mutagenesis is available in Supplementary Methods. Enzyme activity assays. Kinase phosphorylation reactions were performed in a buffered medium containing 20 mM HEPES, pH 7.5 (KOH), 0.1% BSA (w/v), 10 mM MgCl 2 , 1 mM EGTA (pH 7.2), ± 2 mM CaCl 2 (ref. 14) . The phosphorylation reaction contained 40 µM peptide substrate (Syntide-2 (PLARTLSVAGLPGKK); GenScript), 19.48 nM of TgCDPK1, 90 to 0.0005 µM serial dilutions of inhibitor in a total volume of 25 µl, and the reaction was initiated by addition of 10 µM ATP. The reaction was incubated at 30 °C and terminated after 30 min by addition of excess EGTA (5 mM final concentration). Internal positive and negative controls were included in each test. No activity was detected in the absence of peptide substrate. Unused ATP was quantified by luminescence using a nonradioactive Kinaseglo luciferase assay (Promega) as measured by a Chameleon 425-104 multilabel plate scintillation counter (Hidex).
A second enzyme assay, based on the scintillation proximity assay, directly measured the attachment of γ-phosphate to peptide substrate. This assay was used to confirm the K m for ATP and substrate as well as the IC 50 values of the inhibitors. Phosphorylation of the biotinylated peptide substrate (Bio-Syntide-2 (American Peptide Company)) was determined by serial titrations in scintillation proximity assays using streptavidin-coated beads and [γ-33 P]-ATP (PerkinElmer) 34 .
Protein crystallization. Diffraction-quality crystals of native and selenomethionyl-derivatized (SeMet) protein (~18-26 mg ml −1 ) were grown by vapordiffusion equilibration against a reservoir containing 0.18-0.25 M (di-or tri-) ammonium citrate (pH 6.5-7.0), 22-26% (v/v) PEG 3350 and 5 mM dithiothreitol. For inhibitor cocrystals, the crystallization drop was supplemented with 4 mM inhibitor dissolved in dimethylsulfoxide.
Structure determination. Diffraction data were collected at the Stanford Synchrotron Research Lightsource (SSRL) on beamline 9-2 at 100 K on a MarMosaic-325 CCD detector at or near the selenium Kα absorbtion edge. Single-wavelength anomalous dispersion data used to solve the structure were collected from a single crystal of SeMet protein 35 at a wavelength of 0.9792 Å. The other datasets were collected at wavelengths of 0.9792 Å (apo), 0.9791 Å (NA-PP2 complex) and 0.9795 Å (NM-PP1 complex). Data were processed using HKL2000 (ref. 36) .
Initial phases were determined by single-wavelength anomalous dispersion using SOLVE 37 , followed by density modification and automated model building with RESOLVE 37 . Iterated manual model building and restrained refinement continued using Coot 38 and REFMAC5 (ref. 39 ). This structure was used to phase subsequent structures by molecular replacement using Phaser 40 , followed by rebuilding using ARP/wARP 41 . Ideal BKI coordinates and refinement restraints were generated with the PRODRG server 42 . All final models show good Ramachandran statistics 43 . The final apo, NA-PP2 and NM-PP1 models have 97.6%, 98.9% and 98.5% of their residues, respectively, in favored (ϕ,ψ) regions. Gly420 of the NM-PP1 model is the sole (ϕ,ψ) outlier. Data collection and model refinement statistics are presented in Table 1 . More details are presented in Supplementary Methods. Expression of TgCDPK1 variants and growth/invasion assays. The TgCDPK1 coding region or TgCDPK1 G128M mutant were amplified from E. coli expression plasmids with the insertion of 3 adenine nucleotides before the start codon. The second codon was mutated from glycine to alanine for enhanced expression in the parasite 44 . Amplicons were inserted into the BglII/AvrII site of transfection vector pCAT-GFP 45 or pHx-ACP-YFP 46 as in-frame fusions with GFP or YFP under tubA or Gra1 promoter control, respectively. Plasmids encoding HA-tagged
